Drug profile · INN
famotidine
AUSFAM 20
famotidine (AUSFAM 20) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — famotidine
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 11
- Data quality
- 0.89
Quick answer
famotidine (AUSFAM 20) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H2 receptor antagonist
Primary target: Histamine H2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is famotidine?
famotidine (AUSFAM 20) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for famotidine?
AUSFAM 20 is a marketed brand name for famotidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of famotidine?
famotidine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.